Drugs / Inalimarev
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00669734 | Feb 2010 → Sep 2021 overdue | pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00103142 | Feb 2005 → Jun 2009 | colorectal cancer, metastatic malignant neoplasm | Michael Morse, MD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | inalimarev | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00103142 ↗ |
| Modality | Vaccine | “fowlpox-CEA-MUC-1-TRICOM (PANVAC-F) vaccine” NCT00103142 ↗ |
| Route | Subcutaneous | “Given subcutaneously and intradermally” NCT00103142 ↗ |